Last updated: 2026-10-02 22:40:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Insulet Corporation (PODD) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $131.64, with a market capitalization of $9.05B and a P/E ratio of 24.17. Over the past 52 weeks, its price has ranged from $126.40 to $354.88. This page covers its latest market performance, valuation, price trends and company information.
$9.05B | |
$131.82 | |
$354.88 | |
$2.57 | |
$130.79 | |
1.36M | |
1.63M | |
24.17 | |
$354.88 | |
$126.40 | |
-- | |
-- |
Insulet Corporation (PODD) is trading at $130.63 in after-hours trading as of 2026-10-02 22:39:00, down 0.13% ($0.16) from the regular-session close of $130.79.
After-hours trading shows how investors are pricing PODD after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Insulet Corporation (PODD) moved from $136.49 to $131.64, representing a decline of 3.55% ($4.85).
The stock traded between $128.04 and $139.82 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.56 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.3%
PODD is currently trading at $131.64, placing it 2.3% of the way from its 52-week low of $126.40 to its 52-week high of $354.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 5400 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Insulet Corporation (PODD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.